Jacob P. Laubach

18.5k total citations
230 papers, 6.1k citations indexed

About

Jacob P. Laubach is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Jacob P. Laubach has authored 230 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 191 papers in Hematology, 155 papers in Molecular Biology and 101 papers in Oncology. Recurrent topics in Jacob P. Laubach's work include Multiple Myeloma Research and Treatments (189 papers), Protein Degradation and Inhibitors (106 papers) and Peptidase Inhibition and Analysis (54 papers). Jacob P. Laubach is often cited by papers focused on Multiple Myeloma Research and Treatments (189 papers), Protein Degradation and Inhibitors (106 papers) and Peptidase Inhibition and Analysis (54 papers). Jacob P. Laubach collaborates with scholars based in United States, Spain and France. Jacob P. Laubach's co-authors include Paul G. Richardson, Kenneth C. Anderson, Nikhil C. Munshi, Teru Hideshima, Philippe Moreau, Noopur Raje, Jesús F. San Miguel, Sagar Lonial, Constantine S. Mitsiades and Dharminder Chauhan and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Circulation.

In The Last Decade

Jacob P. Laubach

224 papers receiving 6.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jacob P. Laubach United States	41	3.9k	3.9k	2.7k	836	760	230	6.1k
Marc S. Raab Germany	38	3.5k 0.9×	3.4k 0.9×	2.4k 0.9×	519 0.6×	736 1.0×	201	5.5k
Nizar J. Bahlis Canada	38	4.2k 1.1×	3.8k 1.0×	2.8k 1.0×	519 0.6×	642 0.8×	351	6.0k
Peter M. Voorhees United States	33	2.9k 0.7×	3.3k 0.8×	2.7k 1.0×	474 0.6×	600 0.8×	172	5.3k
Saad Z. Usmani United States	45	5.9k 1.5×	4.5k 1.2×	4.4k 1.7×	1.0k 1.2×	902 1.2×	404	7.7k
Eric J. Feldman United States	42	4.3k 1.1×	3.0k 0.8×	1.4k 0.5×	1.8k 2.2×	547 0.7×	195	6.7k
P. Maslak United States	32	1.7k 0.4×	2.8k 0.7×	3.1k 1.1×	683 0.8×	1.1k 1.4×	116	6.3k
George W. Muller United States	45	5.1k 1.3×	4.9k 1.3×	2.9k 1.1×	1.3k 1.6×	1.5k 1.9×	83	8.8k
Gail J. Roboz United States	46	5.0k 1.3×	3.6k 0.9×	1.6k 0.6×	2.0k 2.5×	782 1.0×	317	7.6k
B. Douglas Smith United States	43	4.2k 1.1×	2.8k 0.7×	1.3k 0.5×	1.5k 1.8×	829 1.1×	171	6.3k
Jeffrey E. Lancet United States	48	5.3k 1.3×	3.5k 0.9×	1.8k 0.7×	2.1k 2.5×	625 0.8×	437	7.8k

Countries citing papers authored by Jacob P. Laubach

Since Specialization

Citations

This map shows the geographic impact of Jacob P. Laubach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacob P. Laubach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacob P. Laubach more than expected).

Fields of papers citing papers by Jacob P. Laubach

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacob P. Laubach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacob P. Laubach. The network helps show where Jacob P. Laubach may publish in the future.

Co-authorship network of co-authors of Jacob P. Laubach

This figure shows the co-authorship network connecting the top 25 collaborators of Jacob P. Laubach. A scholar is included among the top collaborators of Jacob P. Laubach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacob P. Laubach. Jacob P. Laubach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mo, Clifton C., Houry Leblebjian, Eileen Regan, et al.. (2025). Outcomes of Melflufen Treatment in Patients With Relapsed/Refractory Multiple Myeloma. European Journal Of Haematology. 114(6). 982–989. 1 indexed citations

Richardson, Paul G., Peter O’Gorman, Lisa Leypoldt, et al.. (2025). Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions. Expert Opinion on Investigational Drugs. 34(7-8). 571–589.

Pawlyn, Charlotte, Fredrik Schjesvold, David A. Cairns, et al.. (2024). Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm. Blood Cancer Journal. 14(1). 134–134. 4 indexed citations

Voorhees, Peter M., Vera J. Suman, Yvonne A. Efebera, et al.. (2024). Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse. Blood Advances. 8(19). 5039–5050. 1 indexed citations

Mo, Clifton C., Andrew J. Yee, Shonali Midha, et al.. (2023). Selinexor: Targeting a novel pathway in multiple myeloma. SHILAP Revista de lepidopterología. 4(3). 792–810. 17 indexed citations

O’Donnell, Elizabeth, Clifton C. Mo, Andrew J. Yee, et al.. (2023). A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial). Blood. 142(Supplement 1). 4671–4671. 2 indexed citations

Frede, Julia, Praveen Anand, Ricardo A. Pinto, et al.. (2021). Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma. Nature Cell Biology. 23(11). 1199–1211. 26 indexed citations

Voorhees, Peter M., Vera J. Suman, Sascha A. Tuchman, et al.. (2021). A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). American Journal of Hematology. 96(12). 1595–1603. 17 indexed citations

Nadeem, Omar, Robert Redd, Alexandra Savell, et al.. (2021). A Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. Blood. 138(Supplement 1). 2749–2749. 5 indexed citations

10.

Kaufman, Jonathan L., Roberto Mina, Jatin J. Shah, et al.. (2020). Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 20(12). 797–803. 5 indexed citations

11.

Ghobrial, Irene M., Chia‐Jen Liu, Robert Redd, et al.. (2019). A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. Clinical Cancer Research. 26(2). 344–353. 79 indexed citations

12.

Treon, Steven P., Kirsten Meid, Joshua Gustine, et al.. (2017). Long-Term Follow-up of Previously Treated Patients Who Received Ibrutinib for Symptomatic Waldenstrom's Macroglobulinemia: Update of Pivotal Clinical Trial. Blood. 130. 2766–2766. 14 indexed citations

13.

Fradley, Michael G., John D. Groarke, Jacob P. Laubach, et al.. (2017). Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. British Journal of Haematology. 180(2). 271–275. 17 indexed citations

14.

Laubach, Jacob P., Philippe Moreau, Jesús F. San Miguel, & Paul G. Richardson. (2015). Panobinostat for the Treatment of Multiple Myeloma. Clinical Cancer Research. 21(21). 4767–4773. 217 indexed citations

15.

Varga, Cindy, Jacob P. Laubach, Teru Hideshima, et al.. (2014). Novel Targeted Agents in the Treatment of Multiple Myeloma. Hematology/Oncology Clinics of North America. 28(5). 903–925. 16 indexed citations

16.

Gaballa, Mahmoud, Jacob P. Laubach, Robert Schlossman, et al.. (2012). Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Review of Hematology. 5(1). 51–68. 24 indexed citations

17.

Chauhan, Dharminder, Jacob P. Laubach, Claire Fabre, et al.. (2012). New Proteasome Inhibitors in Myeloma. Current Hematologic Malignancy Reports. 7(4). 258–266. 73 indexed citations

18.

Jakubı́ková, Jana, Sophia Adamia, Maria Kost‐Alimova, et al.. (2011). Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood. 117(17). 4409–4419. 122 indexed citations

19.

Ghobrial, Irene M., Nikhil C. Munshi, Brianna Harris, et al.. (2011). A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. American Journal of Hematology. 86(7). 573–578. 19 indexed citations

20.

Laubach, Jacob P., Robert Schlossman, Constantine Mitsiades, Kenneth C. Anderson, & Paul G. Richardson. (2011). Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Expert Review of Hematology. 4(1). 51–60. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact